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What is already known about this subject? 
 Total diet replacement (TDR) is an effective method for weight loss in routine 
healthcare settings 
 In the DROPLET randomised trial, doctor referral to a low energy TDR programme 
reduced weight by an additional 7.2 kg at 12 months in comparison to a nurse-led 
behavioural support programme 
 National guidelines in the UK and the US do not recommend TDR programmes for 
routine treatment of obesity  
What does this study add? 
 This is the first cost-effectiveness analysis of a TDR programme for the routine 
treatment of obesity.  
 TDR is projected to be cost-effective at current retail prices under plausible scenarios 
about weight regain after 12 months 
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ABTRACT 
Objective 
To estimate the cost-effectiveness of a commercially provided low energy total diet 
replacement (TDR) programme versus nurse-led behavioural support. 
Methods 
We used a multi-state lifetable model and the weight reduction observed in a randomised 
controlled trial to evaluate the quality-adjusted life-years (QALYs) and direct healthcare 
costs (in UK 2017 prices) over a lifetime with TDR versus nurse-led support in adults who 
were obese, assuming that: i) weight returns to baseline over 5 years, and ii) a 1 kg weight 
loss is maintained after 5 years following TDR.  
Results 
The per-person costs of the TDR and nurse-led programmes were £796 and £34, respectively. 
The incremental cost-effectiveness ratio (ICER) of TDR was £12,955 (95% confidence 
interval: £8,082 to £17,827) assuming all weight lost is regained and £3,203 (£2,580 to 
£3,825) assuming that a 1 kg weight loss is maintained after 5 years. TDR was estimated to 
be more cost-effective (i.e. lower ICERs) in older adults and those with higher body mass 
index, with little difference by gender.  
Conclusions 
At current retail prices and with plausible long-term weight regain trajectories, TDR is 
projected to be cost-effective in obese adults and could be considered as an option to treat 
obesity in routine healthcare settings. 
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INTRODUCTION 
Obesity is a common condition [1] which is associated with higher risks of type-2 diabetes, 
vascular disease, osteoarthritis, and some cancers, among other conditions [2]. As a 
consequence, it accounts for a substantial share of healthcare expenditure. A recent 
systematic review reported that adults with obesity incurred, on average, a third higher total 
annual healthcare expenditures than healthy weight adults [3]. Weight loss achieved with 
lifestyle interventions has been shown to reduce all-cause mortality [4], diabetes incidence 
[5], and cardiovascular risk factors [6].  
Multicomponent behavioural interventions have been shown to reduce weight by 
about 2 kg compared with control at 12 months [7], and have been estimated to be highly 
cost-effective [8, 9]. Very-low-energy diets (providing <800kcal/d) together with behavioural 
programmes reduced weight by an additional 4 kg at 12 months compared to intensive 
specialist-delivered behavioural programmes alone [10]. However, national guidelines do not 
recommend them for routine treatment of obesity [11, 12].  
Total diet replacements (TDR) programmes involve the replacement of foods with 
specially formulated, nutritionally-complete products. Two recent trials have shown that 
similar TDR programmes, providing 810-850 kcal/d, together with behavioural support from 
a health professional or trained counsellor, led to comparable weight losses in routine 
healthcare settings [13, 14]. Although substantially more effective than behavioural 
interventions alone, TDR programmes are typically more costly, and their cost-effectiveness 
is not known.  
In this study we evaluate the long-term effects and cost-effectiveness of doctor 
referral of adults with obesity to a commercially provided low-energy TDR programme 
(Cambridge Weight Plan) using the DROPLET study results [14, 15].   
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METHODS 
The DROPLET trial 
A detailed description of the DROPLET trial is presented elsewhere [15]. In brief, 
278 adults with a BMI >30 kg/m
2
, identified through primary care registers, were recruited 
into the study. Participants were randomly allocated either a behavioural support programme 
delivered by their practice nurse or a low energy total diet replacement (TDR) programme 
offered by a commercial provider, with products comprising an initial 810 kcal/d for 8 weeks, 
followed by gradual food reintroduction for 4 weeks, and a further 12 weeks follow-up, along 
with regular behavioural support (15 sessions over 24 weeks). Both programmes were 
delivered at no cost to participants.  
272 participants contributed data on clinical outcomes (6/278 participants withdrew 
their consent for use of data). These participants were predominantly female (61%), aged 
from 19 to 78 years with a mean age of 47 years (standard deviation [SD] 13) in men and 50 
years (SD 13) in women, and with a mean body mass index (BMI) of 37.2 kg/m
2
 (SD 5.4 
kg/m
2
) [14]. At recruitment, 23% had a diagnosis of hypertension and 15% had type-2 
diabetes; 30% were taking medication for diabetes or hypertension.  
At 12 months, participants allocated the nurse-led behavioural support programme 
had lost, on average, 3.1 kg (SD 7.0 kg), while those allocated TDR lost 10.7 kg (SD 9.6 kg). 
In an intention to treat analysis, adjusting for age, sex, and baseline stratification variables, 
the mean difference in weight loss at 12 months was 7.2 kg (95% confidence interval [CI]: 
4.9 to 9.4) with similar effects observed in subgroups defined by age, sex, or baseline BMI. 
This weight reduction corresponds to a mean difference in BMI of 2.3 kg/m
2
 in men and 2.7 
kg/m
2
 in women. Rates of mild adverse events, defined as those not interfering with normal 
functioning (constipation, fatigue headache, and dizziness), were higher among those 
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allocated TDR, while there was no evidence of a difference in rates of adverse events of 
moderate or greater severity (i.e. events that interfered with normal functioning) between 
treatment groups.  
The PRIMEtime-CE Obesity model 
We estimate the accrual of life-years, quality-adjusted life-years (QALYs), and health 
care costs (in UK 2017 prices) for the UK population by sex and age (in 5-year bands) up to 
age 100 years using an adapted version of the PRIMEtime-CE model [16, 17]. PRIMEtime-
CE Obesity is a population-based proportional multi-state lifetable model that links body 
mass index (BMI) to mortality and non-communicable disease morbidity (type-2 diabetes, 
coronary heart disease [CHD], stroke, and cancers of the breast, colon, liver, kidney, and 
pancreas). A fuller description of the model and all data inputs are detailed in the 
Supplementary Appendix. An R package has been developed to allow easy use of the 
PRIMEtime-CE Obesity model, and is available from 
https://github.com/seamuskent/PRIMEtime-CE-Obesity. 
The PRIMEtime model consists of a lifetable, which estimates life-expectancy, and 
disease lifetables, which estimate the incidence and prevalence of, and mortality from, each 
modelled condition. Disease and mortality rates depend on age, sex, and BMI. The effects of 
weight loss are propagated through the model by affecting general mortality and the 
incidence of each condition. Population impact fractions (PIFs) are calculated for each 
condition and for mortality using the relative risk shift method [18]. PIFs provide an estimate 
of the proportion by which mortality or disease incidence in the population would be reduced 
given a change to the BMI distribution, based on the mean weight loss in the target 
population, the distribution of BMI, and the association between mortality or disease 
incidence and BMI. They are calculated in each year of the model by sex and age group.   
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EQ-5D utilities are calculated for each study year based on the age and sex of 
participants, and the incidence and prevalence of the modelled conditions [19], and combined 
with life-years to estimate quality-adjusted life-years (QALYs). Mean annual NHS costs per 
prevalent case of each modelled condition, calculated from NHS Programme Budgeting 
Returns 2013-14 [20], were used to cost prevalent disease rates in the PRIMEtime model. 
Intervention costs were evaluated externally to the model. All costs were converted to UK 
2016-17 prices using the hospital and community services inflation index [21]. 
Intervention costs 
The cost-effectiveness of the TDR programme is estimated in comparison to a nurse-
led behavioural support programme. The nurse-led support programme is estimated to cost 
£34.06 per-person in year 1, based on an additional 2 minutes of GP time in which patients 
are referred to the nurse-led support programme (£8.24), and 4 attendances with a nurse 
practitioner over 12 weeks, each lasting 10 minutes (£25.82). The TDR programme is 
estimated to cost £796.06 per-person. This is based on an additional 4 minutes of GP time in 
which patients are referred to the programme and their eligibility ascertained (£16.49), 
scheduled medication reviews with GPs on two occasions (at baseline and 4 weeks) for the 
30% of patients taking medication for diabetes or hypertension (£22.69). Finally, based on 
observed attendances with the counsellor (mean 12.3 attendances, comprising 315 meal 
replacement products; see Supplementary Table 1 for further details), we estimated the cost 
of the TDR part of the programme to be £756.88. This was based on the standard costs of the 
programme when provided direct to the public with an average cost per product of £2.40 
(which is priced to incorporate the cost of the behavioural support).  
Weight loss beyond 12 months 
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In the DROPLET trial, participants were followed for 12 months. There is uncertainty 
about the trajectory of weight in both trial arms beyond 12 months. We model, therefore, two 
main scenarios (Figure 1). First, we assume that in both treatment arms weight returns to its 
baseline level in an approximately linear fashion between 12 months and 5 years following 
the start of intervention. This is in line with evidence that, on average, individuals tend to 
regain weight following weight loss [22, 23], and the observed reduction in mean difference 
in weight loss between 6 and 12 months in DROPLET [14]. Second, following the long-term 
weight change observed in the Diabetes Prevention Program Outcomes Study [5], we assume 
that 1 kg weight loss relative to baseline weight is maintained beyond 5 years among 
participants allocated TDR, with weight reaching this level from 12 months in an 
approximately linear fashion.  
Base case analysis 
Outcomes are simulated up to 100 years of age for a hypothetical population of adults 
with obesity, with the same age and sex distribution as of DROPLET study participants, and 
results are averaged over this hypothetical cohort. We also estimate results within population 
groups defined by sex, age in fifteen-year bands (20-34, 35-49, 50-64, and 65-79 years), and 
BMI (30 to <35, 35 to <40, and ≥40 kg/m2), assuming a difference in mean weight loss 
between TDR and nurse-led behavioural programme in each group of 7.2 kg at 12 months.  
We compare the life-years, QALYs, and costs accrued with the two treatment options, 
and calculate the Incremental Cost-Effectiveness Ratio (ICER), which provides an estimate 
of the additional costs of TDR for every additional QALY gained. The National Institute for 
Health and Care Excellence (NICE) typically considers interventions as cost-effective if they 
have an ICER of less than £20,000 per QALY [24]. For some analyses, we calculate net 
monetary benefits (NMBs) which are given as the product of the incremental QALYs and the 
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threshold value (i.e. £20,000 per QALY) minus the incremental costs; a positive NMB 
indicates that TDR is cost-effective at that threshold. 
In the estimation of ICERs and NMBs, future costs and health outcomes are 
discounted at a rate of 1.5% per annum, based on recommendations by NICE for evaluating 
preventative programmes in which benefits are expected to accrue over a long time period 
[25]. When presented separately, life-years and QALYs are not discounted. We perform 
probabilistic sensitivity analysis using 500 Monte Carlo Simulations to estimate the impact of 
uncertainty in healthcare costs, quality-of-life decrements, the associations between BMI and 
disease incidence and mortality, and the effect of TDR on weight loss at 12 months on cost-
effectiveness.  
Scenario and sensitivity analysis 
We undertake a variety of scenario analyses to explore the impact of different 
modelling assumptions. In particular, we explore the impact of: (1) different combinations of 
the rate of weight regain and the mean weight loss maintained in the long-term; (2) different 
total TDR programme costs, including assuming a fixed fee of £907.20 for the TDR 
programme based on the costs that would be incurred under current retail prices if patients 
followed the treatment protocol perfectly; (3) discounting health outcomes and costs at 3.5% 
in line with the NICE guidelines for health technology appraisals [24]; (4) adding further 
healthcare costs by age and sex [20, 26], for health conditions beyond those included in the 
economic model; (5) modelling a direct effect on weight loss on EQ-5D utility using the 
observed difference in EQ-5D per kilogram of weight loss at 12 months in DROPLET of 0.02 
[14], in addition to the effect on QALYs operating through disease incidence; and (6) 
applying the treatment to the general UK population of adults with obesity rather than only to 
participants with characteristics like those enrolled in the DROPLET trial. We also estimate 
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the programme cost at which TDR has an ICER equal to £20,000 per QALY, the threshold 
for cost-effective interventions in UK.   
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RESULTS 
Compared to the nurse-led behavioural support programme, the TDR programme is 
projected to generate an additional 0.069 life-years (95% confidence interval [CI]: 0.049-
0.089) and 0.065 QALYs (0.047-0.084) at an additional discounted cost of £665 (635-696) 
per-person over a person’s lifetime, or £12,955 (8,082-17,827) per QALY gained, assuming 
people return to their baseline weight at 5 years following intervention (Table 1). The higher 
total costs for the TDR programme reflect an additional £762 in intervention costs which is 
only partially offset by £97 (66-127) lower NHS costs related to the modelled diseases. For 
every 100,000 people referred to TDR, it is projected that 50 (34-66) incident CHD events, 
75 (50-100) incident strokes, 899 (658-1140) cases of type-2 diabetes, and 26 (13-38) cancers 
would be avoided.  
If instead it is assumed that participants following TDR maintain a weight 1 kg lower 
than their pre-intervention weight after 5 years, TDR is projected to be even more cost-
effective at £3,203 per QALY gained (95% CI: 2,580-3,825). This reflects higher expected 
gains in life-years (0.287 life-years; 0.237-0.337) and QALYs (0.245; 0.209-0.281), and a 
reduced net discounted cost difference of £519 (471-567), as a result of greater projected 
NHS costs savings. 
The incremental cost per QALY is lower for population groups at higher age, 
independently of sex, under the assumption of a return to pre-intervention weight at 5 years 
post intervention (Figure 2). In this scenario, TDR is cost-effective at a threshold of £20,000 
for adults aged 35 years or older, but not for younger adults. For adults aged less than 50 
years, the confidence intervals around the mean ICERs include the £20,000 per QALY 
threshold. Under the assumption of a maintained 1 kg weight loss after 5 years, TDR is cost-
effective for all adults. Differences in cost-effectiveness by gender are small. In both 
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scenarios of future weight trajectory, the incremental cost per QALY is highest in adults with 
class I obesity (BMI 30 to <35 kg/m
2
) and lowest (i.e., most cost-effective) in adults with 
class III obesity (BMI ≥40 kg/m2), but consistently below the standard threshold of £20,000 
per QALY for all adults irrespective of their BMI at recruitment.  
The longer the duration over which costs and health outcomes are projected, the more 
cost-effectiveness TDR becomes since the costs of treatment are incurred in year 1, while the 
health benefits and healthcare cost savings are accrued in later years. For the total population, 
TDR becomes cost-effective at £20,000 per QALY when outcomes are projections over time 
periods longer than 17 years and 13 years in the scenarios of full weight regain and partial 
maintenance of weight loss, respectively (Figure 3).  
The longer weight remains below its pre-intervention level, and the greater the long-
term weight loss maintained, the more cost-effective a TDR programme would be (Figure 4). 
Assuming a maintained weight loss of at least 1 kg, TDR is cost-effective at £20,000 
regardless of how quickly weight is regained to this level following intervention. In the 
absence of long-term maintenance of weight loss, TDR is cost-effective at £20,000 per 
QALY so long as it takes more than 3 years until lost weight is completely regained.  
Under the assumption of full weight regain at 5 years, a fixed fee for the TDR 
programme of £907.20, discounting costs and health outcomes at 3.5% per year, and 
including additional healthcare costs incurred for diseases beyond those modelled in 
PRIMEtime increase the ICER from £12,955 to £15,551, £17,673, and £15,300, respectively 
(Figure 5). Including an additional direct effect of weight loss on EQ-5D utility reduces the 
ICER to £6,039. Applying the model to the entire UK population of adults with obesity rather 
than trial participants produced very similar results. These alternative scenarios had similar 
14 
 
directional but smaller absolute, impacts on the ICERs when assuming partial maintenance of 
weight loss, with TDR remaining highly cost-effective at £20,000 per QALY in all scenarios.  
The cost-effectiveness of the TDR programme decreases linearly with total 
programme costs (Figure 6). For the TDR programme not to be considered cost-effective at 
£20,000 per QALY, it would have to cost £1,157 or more assuming complete weight regain 
and £3,518 or more assuming 1 kg weight loss is maintained after 5 years. 
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DISCUSSION 
The DROPLET trial demonstrated that GP referral to a specific TDR programme was a safe 
and effective treatment for weight loss in adults with obesity [14]. Here we have provided 
evidence that this TDR programme is also cost-effective under a range of plausible scenarios 
regarding weight regain after 12 months. It is most cost-effective in middle-aged and older 
adults, and those at higher levels of BMI, who face higher immediate risks of obesity-related 
diseases and premature mortality. The cost-effectiveness results were robust to alternative 
modelling assumptions including in the discount rate applied to costs and health benefits and 
the inclusion of further healthcare costs for diseases beyond those modelled in PRIMEtime.  
 This is the first study to estimate the cost-effectiveness of TDR for the routine 
treatment of obesity. Our estimates were informed by effectiveness data from a recent trial 
[14], and we were able to extrapolate results based on estimates of associations between BMI 
and the incidence of obesity-related diseases and mortality from leading epidemiological 
studies. The PRIMEtime-CE model allowed us to model the effect of weight loss on a range 
of obesity-related conditions and account for multi-morbidity [27]. We were also able to 
estimate the impact of small changes in weight, rather than transitions between broad weight 
categories as in many other models [28], on disease incidence and mortality. 
 The results presented herein pertain to a specific TDR programme, namely GP 
referral to a commercially provided low-energy diet programme with behavioural support 
delivered over six months with gradual food reintroduction after three months. The base-case 
cost estimate for the TDR programme reflects observed attendance rates among participants 
in the DROPLET study and current recommended retail prices. In practice it is not clear how 
this or similar interventions would be organised and financed were the NHS to offer them. 
There would be some set up costs in procurement of the service but there may also be 
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opportunities to achieve lower costs of the programme itself through competitive tendering. 
We estimated that a TDR programme delivering the weight loss observed in the DROPLET 
study would be cost-effective at £20,000 per QALY as long as the total programme costs 
were no greater than £1,157, assuming full weight regain at 5 years. However, adherence and, 
accordingly, effectiveness could also differ under alternative TDR schemes. For example, if 
the behavioural support was delivered by healthcare practitioners or a co-payment scheme in 
which patients were expected to contribute to the costs was introduced, adherence to the 
programme, its price, and hence cost-effectiveness might differ.  
There are of course a number of important limitations. First, body weight was only 
measured for 12 months. We made assumptions about the sustainability of weight loss 
beyond 12 months based on previous evidence, although most studies were short in duration 
[22, 23]. In this analysis, we made similar assumptions about weight regain to other studies 
[8] and the cost-effectiveness of TDR was robust to conservative assumptions about weight 
regain. Nevertheless, future research would benefit from a better understanding of the 
durability of weight loss.  
Second, we estimated the impact of weight change on disease incidence and mortality 
from observational studies, which may be subject to bias from residual confounding. Weight 
loss through surgical or non-surgical interventions is associated with reductions in all-cause 
mortality and diabetes incidence, and with diabetes remission [4, 5, 29, 30]. Surgical 
interventions are associated with reductions in the incidence of fatal and non-fatal 
cardiovascular events [31], and also cancer in women but not in men [32]. Reductions in 
cardiovascular events and cancer incidence have not been consistently reported in non-
surgical interventions [4, 6], but this may relate to low-power and insufficient follow-up in 
these studies, or the extent to which the dietary intervention affects cardiovascular risk factors 
[33]. In DROPLET, TDR was shown to improve cardiovascular risk factors at 12 months 
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[14], and in a similar trial among people with recently-diagnosed type-2 diabetes, 45% of 
people offered a TDR programme were in remission at 12 months [13]. Future research 
would benefit from direct randomised evidence on clinical endpoints like disease incidence, 
remission, and mortality, as well as on healthcare costs and health-related quality of life. 
 Third, excess weight has been associated with increased incidence and costs of many 
health conditions not included in PRIMEtime including knee osteoarthritis [2, 34] and  
weight loss can promote diabetes remission which is not included in the model [13, 35]. 
Accordingly we may have under-estimated the healthcare savings accruing from weight loss 
with TDR in obese adults. As is the case with most other analyses, the cost-effectiveness 
analysis was performed from an NHS healthcare perspective, and did not consider wider 
societal costs. It did not incorporate any costs to the patient of attendance at the behavioural 
support sessions but nor did it consider the cost-savings to patients through reduced 
purchases of their usual food. Finally, we did not model the impact of the higher rates of mild 
adverse events among those allocated TDR on health-related quality of life or costs. These 
events, by definition, do not interfere with normal functioning, are confined to the 12 week 
weight loss phase of the programme, and do not entail large healthcare expenditures. Hence, 
their inclusion would not be expected to materially impact on cost-effectiveness.    
To our knowledge, there are no cost-effectiveness analyses of TDR programmes for 
the routine treatment of obesity. A number of cost-effectiveness analyses have been 
undertaken for other surgical, pharmacological, and lifestyle management interventions. 
Comparability across studies is difficult because of major methodological differences 
including the comparator(s) chosen, population studied, time horizon, and assumptions about 
effects of weight loss on quality of life, and weight regain. Bariatric surgery is generally 
found to be cost-effective with ICERs of £2,000 to £4,000 per QALY gained in patients who 
are morbidly obese [36]. Although an expensive procedure at around £10,000 [37], it delivers 
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substantial and sustained weight loss and improved health outcomes [29]. A systematic 
review of the cost-effectiveness of pharmacological treatments reported a median ICER of 
£24,000 per QALY for Orlistat [38]. Orlistat reduces weight by about 2.6 kg at 12 months 
compared to placebo [39], at a cost of around £540 per year [40]. A number of studies have 
reported on the cost-effectiveness of behavioural interventions for weight loss [8, 9, 41-44]. 
Most produce modest reductions in weight at 1-2 years, but because they can typically be 
provided at very low cost, they are often considered cost-effective. For instance, referral to a 
52-week community-based weight-loss group offered by a commercial provider produced an 
additional weight loss of 4 kg at an additional cost of £176.34 compared to brief intervention, 
giving an ICER of £2,394 per QALY over 25 years [8].  
Many previous studies, particularly those of pharmacological interventions, have 
assumed that weight loss has a direct effect on EQ-5D utility. This is probably a major 
determinant of the low ICERs reported [38]. Indeed, in our analysis, assuming such an effect 
substantially reduced the incremental cost per QALY of TDR from £12,955 to £6,039 
assuming full weight regain at 5 years. However, a systematic review and meta-analysis of 
weight loss trials did not find consistent evidence of improvements in health-related quality 
of life following weight loss [45].  
Based on the current retail prices for the diet replacement products, the TDR 
programme used in the DROPLET trial is a cost-effective treatment for reducing weight in 
adults with obesity. Low energy total diet replacement programmes are not currently 
recommended for the routine treatment of obesity [11, 12]. In view of growing clinical and 
economic evidence, the use of, and funding for, such programmes should be reconsidered. 
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TABLES AND FIGURES 
Table 1. Health benefits and healthcare costs over 25-years for nurse-led behavioural 
support and total diet replacement programme 
 Nurse-led 
intervention 
(nurse) 
Total diet 
replacement 
(TDR) 
Mean difference (95% 
CI) 
(TDR vs. nurse) 
 
Weight regained by 5 years following intervention 
Life-years 31.31 31.38 0.069 (0.049, 0.089) 
QALYs 23.19 23.26 0.065 (0.047, 0.084) 
Total costs (£) 7,425 8,090 665 (635, 696) 
   Treatment costs (£) 34 796 762 (762, 762) 
   NHS disease costs (£) 7,390 7,294 -97 (-127, -66) 
ICER (£ per QALY)   12,955 (8,082, 17,827) 
Disease incidence (per 100,000 persons)   
   CHD 10,238 10,188 -50 (-66, -34) 
   Stroke 13,947 13,872 -75 (-100, -50) 
   Type-2 diabetes 51,142 50,243 -899 (-1,140, -658) 
   Cancer* 15,005 14,979 -26 (-38, -13) 
    
Maintained weight loss of 1 kg in TDR arm after 5 years 
Life-years 31.31 31.60 0.287 (0.237, 0.337) 
QALYs 23.19 23.44 0.245 (0.209, 0.281) 
Total costs (£) 7,425 7,944 519 (471, 567) 
   Treatment costs (£) 34 796 762 (762, 762) 
   NHS disease costs (£) 7,390 7,148 -243 (-291, -195) 
ICER (£ per QALY)   3,203 (2,580, 3,825) 
Disease incidence (per 100,000 persons)   
   CHD 10,238 10,031 -206 (-256, -157) 
   Stroke 13,947 13,704 -243 (-356, -130) 
   Type-2 diabetes 51,142 47,020 -4,122 (-4,651, -3,592) 
   Cancer* 15,005 14,902 -102 (-146, -59) 
Values are means (95% confidence intervals). All reported values are discounted at 1.5% per 
annum, except life-years and QALYs which are undiscounted. 
QALYs=Quality-adjusted life-year; ICER=Incremental Cost-Effectiveness Ratio; 
CHD=Coronary heart disease; NHS=National Health Service; TDR=Total diet replacement.  
*Includes cancers of the breast, colon, liver, kidney, and pancreas. 
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Figure 1. Weight loss scenarios 
 
TDR=Total Diet Replacement; kg=kilograms. 
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Figure 2. Incremental cost-effectiveness ratios in subgroups by age, sex, and body mass index 
 
TDR=Total Diet Replacement; kg=kilograms. Error bars show 95% confidence intervals. 
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Figure 3. Net monetary benefit over time under different weight trajectory scenarios 
 
QALY=Quality Adjusted Life Year; TDR=Total Diet Replacement; kg=kilogram. Shaded 
areas show 95% confidence intervals. 
 
27 
 
Figure 4. Incremental cost-effectiveness ratios under different assumptions about future 
weight trajectories 
 
Error bars show 95% confidence intervals. 
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Figure 5. Incremental cost-effectiveness ratios under alternative model assumptions 
 
TDR=Total Diet Replacement; BMI=Body mass index; kg=kilogram. Error bars show 95% confidence intervals. 
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Figure 6. Net monetary benefit by total TDR programme costs under different weight 
trajectory scenarios 
 
TDR=Total Diet Replacement; kg=kilogram; QALY=Quality Adjusted Life Year. Shaded 
areas show 95% confidence intervals. 
 
 
